dupilumab vs SSGJ-611
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
dupilumab · Dupixent
Marketed by Regeneron Pharmaceuticals and partners
NCT01949311 · Phase 3 · completed
This was an explicitly described open-label extension enrolling participants from prior dupilumab atopic dermatitis trials, including the SOLO 1 and SOLO 2 programs, with 2,677 participants receiving dupilumab in a single group. The primary outcomes were safety events rather than a comparative efficacy endpoint, and there was no randomization, blinding, or control arm; therefore, the findings provide limited evidence despite the large enrollment. Its registered primary outcome on ClinicalTrials.gov is "Number of Treatment Emergent Adverse Events (TEAEs)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: November 2026 · NCT06389136 (registry estimate)
Reported efficacy
Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% (met)
Result source: NCT04417894
SSGJ-611
Developed by Sunshine Guojian Pharmaceutical and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07767253 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dupilumab | SSGJ-611 |
|---|---|---|
| EASI-75 | 62.6% vs 29.6%+33 vs placeboNCT0275564921 other results
| —Not posted · NCT06173284 |
| IGA 0/1 with 2-point improvement | —Trial running · NCT06884891 | —Not posted · NCT06173284 |
| EASI-90 | 35.7% vs 7.6%+28.1 vs placeboNCT0227774310 other results
| —Not posted · NCT06173284 |
| EASI, % change | 0.1% vs 21.7%−21.6 vs placeboNCT0239513331 other results
| —Not posted · NCT06173284 |
EASI-75
- dupilumab
- 62.6% vs 29.6%+33 vs placeboNCT02755649
21 other results
- 38.1% vs 8.2% NCT03054428
- 59.1% vs 29.6% NCT02755649
- 41.5% vs 8.2% NCT03054428
- 53% vs 10.7% NCT03346434
- 62.6% vs 72.4% NCT03738397
- 65.2% vs 21.6% NCT02260986
- 51.3% vs 14.7% NCT02277743
- 44.2% vs 11.9% NCT02277769
- 64.1% vs 21.6% NCT02260986
- 63.9% vs 23.2% NCT02260986
- 68.9% vs 23.2% NCT02260986
- 57.3% vs 14.5% NCT03912259
- 52.5% vs 14.7% NCT02277743
- 48.1% vs 11.9% NCT02277769
- 58% vs 26.4% NCT02755649
- 69.7% vs 26.8% NCT03345914
- 56.5% vs 26.4% NCT02755649
- 67.2% vs 26.8% NCT03345914
- 18.2% vs 44.3% NCT03738397
- 53.6% vs 19.6% NCT02210780
- 60.6% vs 29.2% NCT04033367
- SSGJ-611
- —Not posted · NCT06173284
IGA 0/1 with 2-point improvement
- dupilumab
- —Trial running · NCT06884891
- SSGJ-611
- —Not posted · NCT06173284
EASI-90
- dupilumab
- 35.7% vs 7.6%+28.1 vs placeboNCT02277743
10 other results
- 30% vs 7.2% NCT02277769
- 40.2% vs 6% NCT03912259
- 33.2% vs 7.6% NCT02277743
- 30.5% vs 7.2% NCT02277769
- 19% vs 2.4% NCT03054428
- 41.8% vs 7.3% NCT03345914
- 23.2% vs 2.4% NCT03054428
- 25.3% vs 2.8% NCT03346434
- 30.3% vs 7.3% NCT03345914
- 40.3% vs 61.6% NCT03738397
- SSGJ-611
- —Not posted · NCT06173284
EASI, % change
- dupilumab
- 0.1% vs 21.7%−21.6 vs placeboNCT02395133
31 other results
- 6.8% vs 21.7% NCT02395133
- 3.8% vs 21.7% NCT02395133
- -84.9% vs -60.9% NCT02260986
- -73.9% vs -39.5% NCT02277743
- -69.6% vs -33.7% NCT02277769
- -80.5% vs -48.4% NCT02260986
- -87.8% vs -60.9% NCT02260986
- -75.2% vs -39.4% NCT03912259
- -75.2% vs -39.4% NCT03912259
- -79.8% vs -46.6% NCT02755649
- -70.4% vs -35.3% NCT03912259
- -65.8% vs -29.4% NCT03912259
- -55.8% vs -19.3% NCT03912259
- -73.8% vs -39.5% NCT02277743
- -71.6% vs -33.7% NCT02277769
- -81.5% vs -48.4% NCT02260986
- -35.7% vs -10.6% NCT03912259
- -64.8% vs -23.6% NCT03054428
- -82.1% vs -48.6% NCT03345914
- -78.2% vs -46.6% NCT02755649
- -65.9% vs -23.6% NCT03054428
- -70% vs -19.6% NCT03346434
- -78.4% vs -48.6% NCT03345914
- -70.5% vs -20.2% NCT01859988
- -74% vs -23.3% NCT01548404
- -75.5% vs -20.2% NCT01859988
- -64.9% vs -20.2% NCT01859988
- -75.2% vs -5.8% NCT01979016
- -67.4% vs -20.2% NCT01859988
- -46.7% vs -20.2% NCT01859988
- -75.6% vs -52.5% NCT01639040
- SSGJ-611
- —Not posted · NCT06173284
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SSGJ-611: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. dupilumab: 4 of 4 rows · SSGJ-611: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dupilumab |
|---|---|
| Dropout rate | 51.6%a NCT01949311 · Phase 3 · monotherapy show 51 more results7.1%300 mg q2w NCT02277743 · Phase 3 11.7%300 mg qw NCT02277743 · Phase 3 5.6%300 mg q2w NCT02277769 · Phase 3 7.5%300 mg qw NCT02277769 · Phase 3 12.3%300 mg q2w NCT02260986 · Phase 3 12.9%300 mg qw NCT02260986 · Phase 3 8.3%300 mg Q2W/QW NCT02395133 · Phase 3 11.6%300 mg Q4W NCT02395133 · Phase 3 10.7%300 mg Q8W NCT02395133 · Phase 3 95.2%300 mg Q4W NCT03054428 · Phase 3 —200 mg or 300 mg NCT03054428 · Phase 3 96.3%200 mg or 300 mg Q2W NCT03054428 · Phase 3 n/a: no completion milestone300 mg Q4W NCT03345914 · Phase 3 · combination n/a: no completion milestone100 mg or 200 mg Q2W NCT03345914 · Phase 3 · combination 98.8%200 mg or 300 mg Q4W NCT03346434 · Phase 2/3 · combination 0%6 mg/kg NCT03346434 · Phase 2/3 0%6 mg/kg NCT03346434 · Phase 2/3 0%3 mg/kg NCT03346434 · Phase 2/3 10%3 mg/kg NCT03346434 · Phase 2/3 10.4%Q2W NCT04417894 · Phase 3 3.2% NCT05590585 · Phase 4 · registry result, not featured evidence 17.6% NCT03293030 · Phase 4 · registry result, not featured evidence 29.4% NCT03667014 · Phase 4 · registry result, not featured evidence —Atopic Dermatitis Participant NCT04718870 · Phase 4 · registry result, not featured evidence 0%Atopic Dermatitis Participants NCT04718870 · Phase 4 · registry result, not featured evidence 20% NCT04823130 · Phase 4 · registry result, not featured evidence —DB Period: Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 3.9%Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence —OLE Period: Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 0% NCT04447417 · Phase 4 · registry result, not featured evidence 6.9%300 mg EOW NCT03738397 · Phase 3 · registry result, not featured evidence 7.3%300 mg Q2W NCT03912259 · Phase 3 · registry result, not featured evidence 92.5%300 mg Q2W NCT02755649 · Phase 3 · registry result, not featured evidence · combination 92.7%300 mg QW NCT02755649 · Phase 3 · registry result, not featured evidence · combination 0% NCT03359356 · Phase 2 · registry result, not featured evidence —4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 8.2%300 mg qw NCT02210780 · Phase 2 · registry result, not featured evidence 3.7%200 mg qw NCT01979016 · Phase 2 · registry result, not featured evidence 18.8%300 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 15.4%300 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 17.5%300 mg qw NCT01859988 · Phase 2 · registry result, not featured evidence 45.2%200 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 35.4%100 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 25.5%300 mg NCT01548404 · Phase 2 · registry result, not featured evidence —300 mg NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy 0%300 mg QW NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy |
| Discontinued due to AEs | 4%a NCT01949311 · Phase 3 · monotherapy show 51 more results2.7%300 mg q2w NCT02277743 · Phase 3 2.7%300 mg qw NCT02277743 · Phase 3 0.9%300 mg q2w NCT02277769 · Phase 3 1.7%300 mg qw NCT02277769 · Phase 3 0%300 mg q2w NCT02260986 · Phase 3 3.4%300 mg qw NCT02260986 · Phase 3 0%300 mg Q2W/QW NCT02395133 · Phase 3 3.5%300 mg Q4W NCT02395133 · Phase 3 1.2%300 mg Q8W NCT02395133 · Phase 3 —300 mg Q4W NCT03054428 · Phase 3 —200 mg or 300 mg NCT03054428 · Phase 3 —200 mg or 300 mg Q2W NCT03054428 · Phase 3 —300 mg Q4W NCT03345914 · Phase 3 · combination —100 mg or 200 mg Q2W NCT03345914 · Phase 3 · combination —200 mg or 300 mg Q4W NCT03346434 · Phase 2/3 · combination —6 mg/kg NCT03346434 · Phase 2/3 —6 mg/kg NCT03346434 · Phase 2/3 —3 mg/kg NCT03346434 · Phase 2/3 —3 mg/kg NCT03346434 · Phase 2/3 —Q2W NCT04417894 · Phase 3 — NCT05590585 · Phase 4 · registry result, not featured evidence — NCT03293030 · Phase 4 · registry result, not featured evidence — NCT03667014 · Phase 4 · registry result, not featured evidence —Atopic Dermatitis Participant NCT04718870 · Phase 4 · registry result, not featured evidence —Atopic Dermatitis Participants NCT04718870 · Phase 4 · registry result, not featured evidence — NCT04823130 · Phase 4 · registry result, not featured evidence —DB Period: Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 0.8%Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence —OLE Period: Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence — NCT04447417 · Phase 4 · registry result, not featured evidence 0.9%300 mg EOW NCT03738397 · Phase 3 · registry result, not featured evidence 4.9%300 mg Q2W NCT03912259 · Phase 3 · registry result, not featured evidence —300 mg Q2W NCT02755649 · Phase 3 · registry result, not featured evidence · combination —300 mg QW NCT02755649 · Phase 3 · registry result, not featured evidence · combination — NCT03359356 · Phase 2 · registry result, not featured evidence —4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 5.2%300 mg qw NCT02210780 · Phase 2 · registry result, not featured evidence 3.7%200 mg qw NCT01979016 · Phase 2 · registry result, not featured evidence 1.6%300 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 1.5%300 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 3.2%300 mg qw NCT01859988 · Phase 2 · registry result, not featured evidence 4.8%200 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 3.1%100 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 1.8%300 mg NCT01548404 · Phase 2 · registry result, not featured evidence —300 mg NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy 0%300 mg QW NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy |
| Serious AEs | 10.6%a NCT01949311 · Phase 3 · monotherapy show 51 more results3.1%300 mg q2w NCT02277743 · Phase 3 0.9%300 mg qw NCT02277743 · Phase 3 2.5%300 mg q2w NCT02277769 · Phase 3 3.8%300 mg qw NCT02277769 · Phase 3 3.6%300 mg q2w NCT02260986 · Phase 3 3.8%300 mg qw NCT02260986 · Phase 3 3.6%300 mg Q2W/QW NCT02395133 · Phase 3 4.6%300 mg Q4W NCT02395133 · Phase 3 3.6%300 mg Q8W NCT02395133 · Phase 3 0%300 mg Q4W NCT03054428 · Phase 3 0%200 mg or 300 mg NCT03054428 · Phase 3 —200 mg or 300 mg Q2W NCT03054428 · Phase 3 2.5%300 mg Q4W NCT03345914 · Phase 3 · combination 0%100 mg or 200 mg Q2W NCT03345914 · Phase 3 · combination 0%200 mg or 300 mg Q4W NCT03346434 · Phase 2/3 · combination 0%6 mg/kg NCT03346434 · Phase 2/3 0%6 mg/kg NCT03346434 · Phase 2/3 10%3 mg/kg NCT03346434 · Phase 2/3 10%3 mg/kg NCT03346434 · Phase 2/3 4.5%Q2W NCT04417894 · Phase 3 5.6% NCT05590585 · Phase 4 · registry result, not featured evidence 0% NCT03293030 · Phase 4 · registry result, not featured evidence 0% NCT03667014 · Phase 4 · registry result, not featured evidence 0%Atopic Dermatitis Participant NCT04718870 · Phase 4 · registry result, not featured evidence —Atopic Dermatitis Participants NCT04718870 · Phase 4 · registry result, not featured evidence 3.2% NCT04823130 · Phase 4 · registry result, not featured evidence 1.6%DB Period: Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence —Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 0.8%OLE Period: Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 0% NCT04447417 · Phase 4 · registry result, not featured evidence 2.1%300 mg EOW NCT03738397 · Phase 3 · registry result, not featured evidence 1.2%300 mg Q2W NCT03912259 · Phase 3 · registry result, not featured evidence 1.9%300 mg Q2W NCT02755649 · Phase 3 · registry result, not featured evidence · combination 2.7%300 mg QW NCT02755649 · Phase 3 · registry result, not featured evidence · combination 2.5% NCT03359356 · Phase 2 · registry result, not featured evidence 5%4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 10.5%4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 5%2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 3.1%300 mg qw NCT02210780 · Phase 2 · registry result, not featured evidence 0%200 mg qw NCT01979016 · Phase 2 · registry result, not featured evidence 3.1%300 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 4.6%300 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 1.6%300 mg qw NCT01859988 · Phase 2 · registry result, not featured evidence 1.6%200 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 7.7%100 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 1.8%300 mg NCT01548404 · Phase 2 · registry result, not featured evidence 0%300 mg NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy —300 mg QW NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy |
| Most frequent reported AEs | a nasopharyngitis 28.9% dermatitis atopic 16.7% upper respiratory tract infection 13.6% NCT01949311 · Phase 3 · monotherapy show 44 more results300 mg q2w dermatitis atopic 15.3% (placebo 29.7%) nasopharyngitis 11.8% (placebo 9.9%) headache 9.2% (placebo 5.9%) NCT02277743 · Phase 3 300 mg qw injection site reaction 18.8% (placebo 5.9%) nasopharyngitis 11.9% (placebo 9.9%) dermatitis atopic 9.6% (placebo 29.7%) NCT02277743 · Phase 3 300 mg q2w dermatitis atopic 14.4% (placebo 35%) injection site reaction 13.6% (placebo 6.4%) nasopharyngitis 9.7% (placebo 10.7%) NCT02277769 · Phase 3 300 mg qw dermatitis atopic 16.5% (placebo 35%) injection site reaction 13.1% (placebo 6.4%) headache 9.7% (placebo 5.1%) NCT02277769 · Phase 3 300 mg q2w dermatitis atopic 36.4% (placebo 51.1%) nasopharyngitis 23.6% (placebo 19.7%) injection site reaction 14.5% (placebo 7.6%) NCT02260986 · Phase 3 300 mg qw dermatitis atopic 28.9% (placebo 51.1%) nasopharyngitis 20% (placebo 19.7%) injection site reaction 19% (placebo 7.6%) NCT02260986 · Phase 3 300 mg Q2W/QW dermatitis atopic 20.4% (placebo 48.8%) nasopharyngitis 19.2% (placebo 13.4%) upper respiratory tract infection 7.8% (placebo 7.3%) NCT02395133 · Phase 3 300 mg Q4W dermatitis atopic 34.5% (placebo 48.8%) nasopharyngitis 12.6% (placebo 13.4%) bronchitis 5.7% (placebo 1.2%) NCT02395133 · Phase 3 300 mg Q8W dermatitis atopic 32.1% (placebo 48.8%) nasopharyngitis 13.1% (placebo 13.4%) upper respiratory tract infection 8.3% (placebo 7.3%) NCT02395133 · Phase 3 300 mg Q4W dermatitis atopic 19.3% (placebo 24.7%) nasopharyngitis 12% (placebo 4.7%) upper respiratory tract infection 8.4% (placebo 17.6%) NCT03054428 · Phase 3 200 mg or 300 mg dermatitis atopic 18.3% (placebo 24.7%) upper respiratory tract infection 12.2% (placebo 17.6%) headache 11% (placebo 10.6%) NCT03054428 · Phase 3 300 mg Q4W nasopharyngitis 12.5% (placebo 6.7%) upper respiratory tract infection 11.7% (placebo 10%) dermatitis atopic 6.7% (placebo 14.2%) NCT03345914 · Phase 3 · combination 100 mg or 200 mg Q2W upper respiratory tract infection 9.8% (placebo 10%) dermatitis atopic 8.2% (placebo 14.2%) nasopharyngitis 6.6% (placebo 6.7%) NCT03345914 · Phase 3 · combination 200 mg or 300 mg Q4W dermatitis atopic 14.5% (placebo 30.8%) nasopharyngitis 8.4% (placebo 9%) upper respiratory tract infection 6% (placebo 9%) NCT03346434 · Phase 2/3 · combination 6 mg/kg nasopharyngitis 20% (placebo 9%) cough 10% (placebo 6.4%) dermatitis atopic 10% (placebo 30.8%) NCT03346434 · Phase 2/3 6 mg/kg cough 10% (placebo 6.4%) nasopharyngitis 10% (placebo 9%) skin abrasion 10% (placebo 0%) NCT03346434 · Phase 2/3 3 mg/kg pyrexia 20% (placebo 9%) constipation 10% (placebo 0%) cough 10% (placebo 6.4%) NCT03346434 · Phase 2/3 3 mg/kg dermatitis atopic 10% (placebo 30.8%) impetigo 10% (placebo 7.7%) nasopharyngitis 10% (placebo 9%) NCT03346434 · Phase 2/3 Q2W nasopharyngitis 23.9% (placebo 12.1%) covid-19 16.4% (placebo 21.2%) upper respiratory tract infection 10.4% (placebo 4.5%) NCT04417894 · Phase 3 eye irritation 35.3% oral/facial herpes simplex 17.6% covid19 (moderate) 5.9% NCT03293030 · Phase 4 · registry result, not featured evidence eye redness 2.9% eyelid swelling 2.9% facial erythema 2.9% NCT03667014 · Phase 4 · registry result, not featured evidence dermatitis atopic 39.1% medical device site haemorrhage 26.1% upper respiratory tract infection 17.4% NCT04718870 · Phase 4 · registry result, not featured evidence headache 22.6% dermatitis atopic 9.7% conjunctivitis 6.5% NCT04823130 · Phase 4 · registry result, not featured evidence conjunctivitis 9.4% (placebo 4.9%) headache 7.1% (placebo 8.2%) dermatitis atopic 3.1% (placebo 13.1%) NCT04033367 · Phase 4 · registry result, not featured evidence accidental overdose 12.3% (placebo 0%) conjunctivitis 2.5% (placebo 4.9%) dermatitis atopic 2.5% (placebo 13.1%) NCT04033367 · Phase 4 · registry result, not featured evidence injection site reaction 19.2% arthralgia 11.5% food allergy 7.7% NCT04447417 · Phase 4 · registry result, not featured evidence 300 mg EOW conjunctivitis 10.6% dermatitis atopic 9.7% nasopharyngitis 8.2% NCT03738397 · Phase 3 · registry result, not featured evidence 300 mg Q2W dermatitis atopic 43.9% (placebo 49.4%) upper respiratory tract infection 17.1% (placebo 12%) protein urine present 11% (placebo 10.8%) NCT03912259 · Phase 3 · registry result, not featured evidence 300 mg Q2W nasopharyngitis 20.6% (placebo 16.7%) conjunctivitis allergic 15% (placebo 6.5%) conjunctivitis 11.2% (placebo 3.7%) NCT02755649 · Phase 3 · registry result, not featured evidence · combination 300 mg QW nasopharyngitis 16.4% (placebo 16.7%) headache 10% (placebo 9.3%) conjunctivitis allergic 9.1% (placebo 6.5%) NCT02755649 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 15% (placebo 10%) other orthopedic injuries/procedures 12.5% (placebo 5%) conjuctivitis 10% (placebo 0%) NCT03359356 · Phase 2 · registry result, not featured evidence 4 mg/kg nasopharyngitis 40% dermatitis atopic 15% abdominal pain upper 10% NCT02407756 · Phase 2 · registry result, not featured evidence 4 mg/kg nasopharyngitis 52.6% cough 36.8% dermatitis atopic 26.3% NCT02407756 · Phase 2 · registry result, not featured evidence 2mg/kg dermatitis atopic 10% influenza 10% nasopharyngitis 10% NCT02407756 · Phase 2 · registry result, not featured evidence 2mg/kg dermatitis atopic 27.8% nasopharyngitis 27.8% cheilitis 5.6% NCT02407756 · Phase 2 · registry result, not featured evidence 300 mg qw upper respiratory tract infection 11.3% (placebo 14.4%) conjunctivitis 8.2% (placebo 0%) headache 5.2% (placebo 3.1%) NCT02210780 · Phase 2 · registry result, not featured evidence 200 mg qw dermatitis atopic 14.8% (placebo 14.8%) upper respiratory tract infection 14.8% (placebo 14.8%) nasopharyngitis 11.1% (placebo 18.5%) NCT01979016 · Phase 2 · registry result, not featured evidence 300 mg q2w nasopharyngitis 25% (placebo 26.2%) dermatitis atopic 20.3% (placebo 16.4%) upper respiratory tract infection 9.4% (placebo 18%) NCT01859988 · Phase 2 · registry result, not featured evidence 300 mg q4w nasopharyngitis 32.3% (placebo 26.2%) dermatitis atopic 15.4% (placebo 16.4%) headache 7.7% (placebo 3.3%) NCT01859988 · Phase 2 · registry result, not featured evidence 300 mg qw nasopharyngitis 25.4% (placebo 26.2%) dermatitis atopic 12.7% (placebo 16.4%) headache 12.7% (placebo 3.3%) NCT01859988 · Phase 2 · registry result, not featured evidence 200 mg q2w nasopharyngitis 26.2% (placebo 26.2%) headache 14.8% (placebo 3.3%) dermatitis atopic 13.1% (placebo 16.4%) NCT01859988 · Phase 2 · registry result, not featured evidence 100 mg q4w nasopharyngitis 30.8% (placebo 26.2%) dermatitis atopic 16.9% (placebo 16.4%) headache 10.8% (placebo 3.3%) NCT01859988 · Phase 2 · registry result, not featured evidence 300 mg nasopharyngitis 40% (placebo 18.5%) headache 16.4% (placebo 13%) conjunctivitis 14.5% (placebo 3.7%) NCT01548404 · Phase 2 · registry result, not featured evidence 300 mg nasopharyngitis 23.8% (placebo 20%) headache 14.3% (placebo 10%) oropharyngeal pain 14.3% (placebo 10%) NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dupilumab
show 26 more results
show 19 more results
show 11 more results
show 22 more results
show 26 more results
show 18 more results
+ 127 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dupilumab's landscape · SSGJ-611's landscape